AUTHORS
Ashlie Marie Munoz, PhD, Miso Park, PhD2, Dandan Zhao, PhD3, Fang Chen, PhD4, Alex Zhu5, Melissa Valerio, PhD6, Cheng-Fu Kuo, PhD7, Le Xuan Truong Nguyen, PhD8, Lucy Ghoda, PhD9, Christine Brown, PhD10, John Williams, PhD11, Bin Zhang, PhD12, Guido Marcucci, MD13
AFFILIATIONS
1 City of Hope National Medical Center and Beckman Research Institute, Duarte, California, United States
2 City of Hope National Medical Center and Beckman Research Institute, Duarte, California, United States
3 City of Hope National Medical Center and Beckman Research Institute, Duarte, California, United States
4 City of Hope National Medical Center and Beckman Research Institute, Duarte, California, United States
5 City of Hope National Medical Center and Beckman Research Institute, Duarte, California, United States
6 City of Hope National Medical Center and Beckman Research Institute, Duarte, California, United States
7 City of Hope National Medical Center and Beckman Research Institute, Duarte, California, United States
8 City of Hope National Medical Center and Beckman Research Institute, Duarte, California, United States
9 City of Hope National Medical Center and Beckman Research Institute, Duarte, California, United States
10 City of Hope National Medical Center and Beckman Research Institute, Duarte, California, United States
11 City of Hope National Medical Center and Beckman Research Institute, Duarte, California, United States
12 City of Hope National Medical Center and Beckman Research Institute, Duarte, California, United States
13 City of Hope National Medical Center and Beckman Research Institute, Duarte, California, United States
ABSTRACT
Background: Although CAR T-cell therapy has transformed the treatment of B-cell malignancies, its application in AML has been limited by the lack of leukemia-specific targets, antigen heterogeneity, antigen downregulation, persistence of leukemia stem cells (LSCs), and profound immune suppression within the bone marrow (BM) microenvironment, which also impairs CAR T-cell antileukemic activity. Next-generation CAR T-cell therapies are therefore urgently needed to overcome these barriers. We previously showed that interleukin-1 receptor accessory protein (IL1RAP) is highly expressed on AML blasts and LSCs but minimally expressed on normal hematopoietic stem cells (HSCs), and that IL1RAP-targeted immunotherapies selectively eradicate AML cells while sparing HSCs (J Hematol Oncol 2024 & 2025). Building on these findings, we developed a programmable IL1RAP CAR T-cell platform designed to overcome antigen heterogeneity, antigen downregulation, and adaptive immune resistance.
Methods: We engineered a first-in-class programmable IL1RAP meditope-enabled CAR (meCAR) by incorporating a meditope (me)-binding pocket into the IL1RAP scFab, enabling post-infusion retargeting through meditope peptide-fused adaptor Fabs (mpFabs). mpFabs were engineered to target the AML-associated antigens CD33 and CD123, as well as the immune checkpoint ligands PD-L1 and B7-H3, which impair T-cell activity. To improve in vivo pharmacokinetics (i.e., serum half-life), each adaptor incorporated a serum albumin-binding peptide. Binding of the mpFabs to their target antigens and the meCAR binding pocket was characterized by surface plasmon resonance and flow cytometry. The antileukemic activity of IL1RAP meCAR T cells, with or without mpFabs, was evaluated in vitro (0.098–100 nM; E:T ratio, 1:8) and in IL1RAP-knockout (KO) MOLM14 cell line-derived xenograft (CDX) models (10 or 30 μg/mouse).
Results: Incorporation of the me-binding pocket did not compromise CAR function. IL1RAP meCAR T cells retained activation, cytokine production, and cytotoxicity comparable to conventional IL1RAP CAR T cells lacking the me-binding pocket, effectively eliminating IL1RAP-high AML cell lines and primary patient samples in vitro and demonstrating comparable survival benefit in MOLM14 CDX models. Furthermore, the engineered me-binding domain enabled labeling, tracking, and isolation of meCAR T cells to assess CAR T persistence, trafficking, and function.
To model clinically relevant antigen heterogeneity and antigen downregulation, we generated IL1RAP-KO and IL1RAP-KO/CD33-KO MOLM14 cells by CRISPR/Cas9-mediated gene editing. The mpCD33 redirected IL1RAP meCAR T cells to selectively eliminate IL1RAP-KO/CD33-positive AML cells but not IL1RAP-KO/CD33-KO cells, thereby confirming adaptor-dependent antigen specificity. Both mpCD33 and mpCD123 restored potent, dose-dependent cytotoxicity of IL1RAP meCAR T cells toward IL1RAP-KO AML cells, whereas a non-targeting control mpFab had no effect. In IL1RAP-KO MOLM14 CDX models, IL1RAP meCAR T cells alone failed to control leukemia progression. In contrast, co-administration of mpCD33 or mpCD123 successfully redirected IL1RAP meCAR T cells against IL1RAP-KO AML cells, significantly reducing leukemic burden and prolonging survival (mpCD33 vs control mpFab: 29 vs 23 days, P = 0.0018; mpCD123 vs control mpFab: 50 vs 29 days, P = 0.0017), demonstrating effective in vivo pharmacologic retargeting.
To investigate adaptive immune resistance, we evaluated immune checkpoint ligand expression on AML cells. B7-H3 was constitutively expressed at high levels on AML cells, PD-L1 expression was low at baseline in AML cell lines and primary AML samples and induced following IFN-γ stimulation. In co-culture experiments, mpPD-L1 and mpB7-H3 successfully redirected IL1RAP meCAR T cells against checkpoint ligand-expressing AML cells, producing potent antileukemic activity in vitro and significantly reducing leukemic burden in AML CDX models in vivo. Survival studies are ongoing.
Conclusions: We developed a programmable IL1RAP meCAR T-cell platform that enables post-infusion retargeting to overcome antigen heterogeneity, antigen downregulation, and adaptive immune resistance. This clinically translatable strategy has the potential to improve the durability and efficacy of CAR T-cell therapy for AML by targeting both AML blasts and LSCs. IND-enabling studies of the IL1RAP meCAR T-cell are ongoing.
DISCLOSURES
Ashlie Marie Munoz, PhD: No relevant conflicts of interest to declare.